In this issue:
- Nocturnal baricitinib improves response in RA
- Persistence of T-cell response to SARS-COV-2 vaccination in rituximab-treated RA
- Aortic complications in polymyalgia rheumatica and GCA
- Relma-cel for SLE
- Major adverse CV event risk following targeted RA therapy
- Extramusculoskeletal manifestations in upadacitinib-treated PsA or axial SpA
- Genetic landscape and novel inflammatory biomarkers in AOSD
- Effect of depressive symptoms on treatment response in axial SpA
- Clinical predictors of flare and drug-free remission in RA
- Metformin for knee OA in overweight or obese patients
Please login below to download this issue (PDF)